1-20 of 22
Eric Van Cutsem
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Eric Van Cutsem, Joelle Collignon, Rikke L. Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Audrius Ivanauskas, Dirk Arnold, Edita Baltruskeviciene, Per Pfeiffer, Jeffrey Yachnin, Susanne Magnusson, Camilla Rydberg Millrud, Annika Sanfridson, Nedjad Losic, Ignacio Garcia-Ribas, Dominique Tersago, Ahmad Awada
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5293–5303.
https://doi.org/10.1158/1078-0432.CCR-24-0645
Published: 02 December 2024
View articletitled, Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Open the PDF for Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3686–3694.
https://doi.org/10.1158/1078-0432.CCR-21-4021
Published: 02 September 2022
View articletitled, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Open the PDF for Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract PO002: Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing

Sarah Cappuyns, Gino Philips, Vincent Vandecaveye, Chris Verslype, Eric Van Cutsem, Diether Lambrechts, Jeroen Derkervel
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17_Supplement): PO002.
https://doi.org/10.1158/1557-3265.LIVERCA22-PO002
Published: 01 September 2022
View articletitled, Abstract PO002: Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing
Journal Articles

Abstract PR03: Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing

Sarah Cappuyns, Gino Philips, Vincent Vandecaveye, Chris Verslype, Eric Van Cutsem, Diether Lambrechts, Jeroen Derkervel
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17_Supplement): PR03.
https://doi.org/10.1158/1557-3265.LIVERCA22-PR03
Published: 01 September 2022
View articletitled, Abstract PR03: Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing
Journal Articles

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3489–3498.
https://doi.org/10.1158/1078-0432.CCR-22-0121
Published: 15 August 2022
View articletitled, Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Open the PDF for Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study in another window
Includes: Supplementary data
Journal Articles

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Joseph Chao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 1923–1931.
https://doi.org/10.1158/1078-0432.CCR-20-2980
Published: 01 April 2021
View articletitled, Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Open the PDF for Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10 in another window
Journal Articles

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O'Dwyer, Filip De Vos, Eric Van Cutsem, John M. Millholland, Jan C. Brase, Fatima Rangwala, Eduard Gasal, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2466–2476.
https://doi.org/10.1158/1078-0432.CCR-19-3579
Published: 01 June 2020
View articletitled, BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Open the PDF for BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial

Eric Van Cutsem, Caroline Paccard, Marielle Chiron, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 717–725.
https://doi.org/10.1158/1078-0432.CCR-19-1985
Published: 03 February 2020
View articletitled, Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
Open the PDF for Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors

Eric Van Cutsem, Boguslawa Karaszewska, Yoon-Koo Kang, Hyun Cheol Chung, Veena Shankaran, Salvatore Siena, Ning F. Go, Hui Yang, Marco Schupp, David Cunningham
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2414–2423.
https://doi.org/10.1158/1078-0432.CCR-18-1337
Published: 15 April 2019
View articletitled, A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors
Open the PDF for A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors in another window
Journal Articles

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Timothy J. Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor E. Ciuleanu, Laslo Roman, Eric Van Cutsem, Pei He, Hua Yu, Reija Koukakis, Jan-Henrik Terwey, Andre S. Jung, Roger Sidhu, Scott D. Patterson
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5469–5479.
https://doi.org/10.1158/1078-0432.CCR-15-0526
Published: 14 December 2015
View articletitled, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Open the PDF for Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Philippe L. Bedard, Josep Tabernero, Filip Janku, Zev A. Wainberg, Luis Paz-Ares, Johan Vansteenkiste, Eric Van Cutsem, José Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep Le, Kirsten Carter, David Demanse, Denes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 730–738.
https://doi.org/10.1158/1078-0432.CCR-14-1814
Published: 16 February 2015
View articletitled, A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Open the PDF for A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Heterogeneity of EGFR and HER2 gene status by fluorescent in situ hybridization in colorectal cancer

Nicola Personeni, Gert De Hertogh, Maria Debiec-Rychter, Jef De Schutter, Karel Geboes, Eric Van Cutsem, Sabine Tejpar
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B80.
Published: 15 August 2014
View articletitled, Heterogeneity of EGFR and HER2 gene status by fluorescent in situ hybridization in colorectal cancer
Journal Articles

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith Mitchell, Irina Davidenko, Joe Stephenson, Elena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4240–4250.
https://doi.org/10.1158/1078-0432.CCR-13-2752
Published: 13 August 2014
View articletitled, Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Open the PDF for Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients

Jeroen Dekervel, Daphne Hompes, Hannah van Malenstein, Dusan Popovic, Xavier Sagaert, Bart De Moor, Eric Van Cutsem, André D'Hoore, Chris Verslype, Jos van Pelt
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2159–2168.
https://doi.org/10.1158/1078-0432.CCR-13-2958
Published: 15 April 2014
View articletitled, Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
Open the PDF for Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2541–2550.
https://doi.org/10.1158/1078-0432.CCR-13-0107
Published: 30 April 2013
View articletitled, Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Open the PDF for Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial in another window
Includes: Supplementary data
Journal Articles

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Alex Parker, Salvatore Siena, Eric Van Cutsem, Jing Huang, Yves Humblet, Jean-Luc Van Laethem, Thierry André, Jeffrey Wiezorek, David Reese, Scott D. Patterson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1902–1912.
https://doi.org/10.1158/1078-0432.CCR-12-1913
Published: 02 April 2013
View articletitled, Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Open the PDF for Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma

Hannah van Malenstein, Olivier Gevaert, Louis Libbrecht, Anneleen Daemen, Joke Allemeersch, Frederik Nevens, Eric Van Cutsem, David Cassiman, Bart De Moor, Chris Verslype, Jos van Pelt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (16): 4278–4288.
https://doi.org/10.1158/1078-0432.CCR-09-3274
Published: 11 August 2010
View articletitled, A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma
Open the PDF for A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer

Hans Prenen, Sabine Tejpar, Eric Van Cutsem
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 2921–2926.
https://doi.org/10.1158/1078-0432.CCR-09-2029
Published: 31 May 2010
View articletitled, New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Open the PDF for New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer in another window
Journal Articles

Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial

Fred T. Bosman, Pu Yan, Sabine Tejpar, Roberto Fiocca, Eric Van Cutsem, Richard D. Kennedy, Daniel Dietrich, Arnaud Roth
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5528–5533.
https://doi.org/10.1158/1078-0432.CCR-09-0741
Published: 31 August 2009
View articletitled, Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial
Open the PDF for Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial in another window
Journal Articles

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3184–3188.
https://doi.org/10.1158/1078-0432.CCR-08-2961
Published: 30 April 2009
View articletitled, PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Open the PDF for PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer in another window